Full text
Earnings transcript
Read the complete earnings call transcript.
HROW
Harrow Health, Inc.
$29.05
0.51
(1.77%)
| Exchange: | NASDAQ |
| Market Cap: | 1.089B |
| Shares Outstanding: | 36.76M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – Specialty & GenericView industry performance | |||||
| CEO: | Mark L. Baum | |||||
| Full Time Employees: | 373 | |||||
| Address: |
| |||||
| Website: | https://www.harrow.com |
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company’s portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Click to read more…
Revenue Segmentation
Revenue by type
HROW full analysis
Welcome to MARKETSNAP’s SWOT analysis for Harrow, a company that might not be on everyone’s radar just yet, but one that’s making some interesting moves in the healthcare space. If you’re a long-term investor looking for potential in the pharmaceutical and eye care sector, stick around because we’re diving deep into what makes Harrow tick, what’s holding it back, and where it could be headed. Let’s break it down with a full SWOT analysis, some recent updates, and key insights…
Industry Peers
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
| HROW | Harrow Health, Inc. | 1.1B | — | — | 1.8% |
 AMPH | Amphastar Pharmaceuticals, Inc. | 1.2B | 15.9 | 9.6 | 5.9% |
 CRON | Cronos Group Inc. | 1.3B | 17.6 | 20.6 | 0.0% |
 COLL | Collegium Pharmaceutical, Inc. | 783.9M | 15.6 | 3.2 | 6.1% |
 PCRX | Pacira BioSciences, Inc. | 1.5B | 103 | 12.6 | 1.4% |
 ETON | Eton Pharmaceuticals, Inc. | 1.5B | 112 | 46.9 | 20.4% |
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 130,193 | 199,614 | 272,303 |
| Gross Profit | 90,553 | 150,369 | 204,369 |
| EBITDA | 13,151 | 23,612 | 42,133 |
| Operating Income | 431 | 8,822 | 38,609 |
| Net Income | -24,411 | -17,481 | -5,139 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 312,164 | 388,971 | 399,482 |
| Total Liabilities | 241,753 | 319,674 | 347,391 |
| Total Stockholders Equity | 70,766 | 69,652 | 52,446 |
| Total Debt | 190,502 | 228,828 | 251,976 |
| Cash and Cash Equivalents | 74,085 | 47,247 | 72,927 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 3,840 | -22,202 | 0 |
| Capital Expenditure | -152,553 | -38,674 | 0 |
| Free Cash Flow | -148,713 | -60,876 | 0 |
| Net Income | -24,411 | -17,481 | 0 |
| Net Change in Cash | -22,185 | -26,838 | 25,680 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 940,170.106 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 1,081,723.568 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 1,018,812 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 505,525.283 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 565,913.416 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 539,074.557 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 237,619.993 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 285,326.618 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 264,123.919 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 208,889.350 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 240,340.053 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 226,362.203 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 7.190 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 7.760 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 6.460 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 2 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Revenue Growth: Harrow reported total revenue of $63.7 million in Q2 2025, reflecting robust top-line growth as highlighted in the earnings call transcript. This performance indicates effective market penetration and product demand within the healthcare sector.
- Operational Efficiency: The company’s gross profit margin and net profit margin (as per Key Metrics TTM) suggest a solid ability to manage costs relative to revenue, providing a competitive edge in the industry.
- Focused Commercial Strategy: As noted in the Q2 2025 earnings call, Harrow is leveraging its commercial infrastructure to drive product uptake, particularly in key segments, which supports sustained revenue streams.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates HROW intrinsic value between $99.72 – $109.67 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about HROW valuation
Is Harrow Health, Inc. (HROW) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Harrow Health, Inc. (HROW) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is HROW a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether HROW trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is HROW’s P/E ratio?
You can see HROW’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for HROW?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is HROW a good long-term investment?
Whether HROW fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
HROW
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.77
Trading Metrics:
| Open: | 28.41 | Previous Close: | 28.54 | |
| Day Low: | 28.39 | Day High: | 29.54 | |
| Year Low: | 26.96 | Year High: | 54.85 | |
| Price Avg 50: | 32.38 | Price Avg 200: | 38.15 | |
| Volume: | 308433 | Average Volume: | 587143 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
